CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients

References

• Patankar MS, Jing Y, Morrison JC, Belisle JA, Lattanzio FA, Deng Y, Wong NK. Potent suppression of natural killer cell response. Gynecol Oncol. 2005;99:704–13. doi:10.1016/j.ygyno.2005.07.030. PMID:16126266.
   PubMed Web of Science ®Google Scholar
• Gubbels JA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, Petrie S, Migneault M, Rancourt C, Connor JP, Patankar MS. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 2010;9:11. doi:10.1186/1476-4598-9-11. PMID:20089172.
   PubMed Web of Science ®Google Scholar
• Belisle JA, Gubbels JA, Raphael CA, Migneault M, Rancourt C, Connor JP, Patankar MS. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16. Immunology. 2007;122:418–29. doi:10.1111/j.1365-2567.2007.02660.x. PMID:17617155.
   PubMed Web of Science ®Google Scholar
• Kline JB, Kennedy RP, Albone E, Chao Q, Fernando S, McDonough JM, Rybinski K, Wang W, Somers EB, Schweizer C, Grasso L, Nicolaides NC. Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc receptor engagement. OncoTarget. 2017;8:52045–60. doi:10.18632/oncotarget.19090. PMID:28881712.
   PubMed Web of Science ®Google Scholar
• Wang W, Somers EB, Ross EN, Kline JB, O'Shannessy DJ, Schweizer C., Weil S, Grasso L, Nicolaides NC. FCGR2A and FCGR3A genotype correlates with farletuzumab response in patients with first relapsed ovarian cancer exhibiting low CA125. Cytogenet Genome Res. 2017;152:169–79. doi:10.1159/000481213. PMID:29041009.
   PubMedGoogle Scholar
• Vergote I, Armstrong DJ, Scambia G, Teneriello M, Sehouli J, Schweizer C, et al.. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 2016;34:2271–8. doi:10.1200/JCO.2015.63.2596. PMID:27001568.
   PubMed Web of Science ®Google Scholar
• Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gyn Oncol Res Prac. 2016;3:11–25. doi:10.1186/s40661-016-0033-6.
   PubMedGoogle Scholar
• Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010;16:6132–8. doi:10.1158/1078-0432.CCR-10-2275. PMID:21037025.
   PubMed Web of Science ®Google Scholar
• Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, et al. Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 2015;33:380–8. doi:10.1007/s10637-014-0196-0. PMID:25502863.
   PubMed Web of Science ®Google Scholar
• Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007;7:20–30. PMID:18088084.
   PubMedGoogle Scholar
• Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M, Miyajima A. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2014;279:9190–8. doi:10.1074/jbc.M312372200.
   Google Scholar
• Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan, I. Inhibition of mesothelin-CA125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: implications for cancer therapy. Lung Cancer. 2010;68:455–9. doi:10.1016/j.lungcan.2009.07.016. PMID:19744744.
   PubMed Web of Science ®Google Scholar
• Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, et al. Phase II clinical trial of amatuximab, a chimeric anti-mesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20:5927–36. doi:10.1158/1078-0432.CCR-14-0804. PMID:25231400.
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44. doi:10.1200/JCO.2003.11.136. PMID:12860938.
   PubMed Web of Science ®Google Scholar
• Miller R, Siegmund D. Maximally selected chi square statistics. Biometrics. 1982;38:1011–6. doi:10.2307/2529881.
   Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. doi:10.1093/jnci/92.3.205. PMID:10655437.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric-estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81. doi:10.1080/01621459.1958.10501452.
   Web of Science ®Google Scholar
• Ocana A, Tannock IF. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103:16–20. doi:10.1093/jnci/djq463. PMID:21131576.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14:500–8. doi:10.1245/s10434-006-9192-8. PMID:17151789.
   PubMed Web of Science ®Google Scholar
• Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BWS. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? Lung Cancer. 2013;80:39–44. doi:10.1016/j.lungcan.2012.12.008. PMID:23357461.
   PubMed Web of Science ®Google Scholar
• Pass HI, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, et al. Supplementary prognostic variables for pleural mesothelioma: A report from the IASLC staging committee. J Thorac Oncol. 2014;9:856–64. doi:10.1097/JTO.0000000000000181. PMID:24807157.
   PubMed Web of Science ®Google Scholar
• Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I, and Dimitrov DS. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol Cancer Ther. 2009;8:1113–8. doi:10.1158/1535-7163.MCT-08-0945. PMID:19417159.
   PubMed Web of Science ®Google Scholar
• Wong NK, Easton RL, Panico M, Sutton-Smith M, Morrison JC, Lattanzio FA, Morris HR, Clark GF, Dell A, Patankar MS. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J Biol Chem. 2003;278:28619–34. doi:10.1074/jbc.M302741200. PMID:12734200.
   PubMed Web of Science ®Google Scholar
• Gunn B, Schneider J, Shansab M, Bastian AR, Fahrbach K, Smith A, et al.. Enhanced binding of antibodies generated during chronic HIV infection to mucus component MUC16. Mucosal Immunol. 2016;9:1549–58. doi:10.1038/mi.2016.8. PMID:26960182.
   PubMed Web of Science ®Google Scholar
• O'Shannessy, DJ, Bendas K, Schweizer C, Wang W, Albone E, Somers EB, Weil S, Meredith RK, Wustner J, Grasso L, et al. Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer. Genomics. 2017;109:251–7. doi:10.1016/j.ygeno.2017.04.006. PMID:28450240.
   PubMed Web of Science ®Google Scholar
• Cheng X, Gou HF, Liu JY, Luo DY, Qiu M. Clinical significance of serum CA125 in diffuse malignant mesothelioma. SpringerPlus. 2016;5:368–76. doi:10.1186/s40064-016-1998-7. PMID:27066377.
   PubMed Web of Science ®Google Scholar
• Fehm T, Beck E, Valerius T, Gramatzki M, Jager W. CA125 elevation in patients with malignant lymphomas. Tumour Biology. 1998;19:283–9. doi:10.1159/000030019. PMID:9679739.
   PubMed Web of Science ®Google Scholar
• Gupta A, Hussein Z, Hassan R, Wustner J, Maltzman JD, Wallin BA. Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection. Cancer Chemother Pharmacol. 2016;77:733–43. doi:10.1007/s00280-016-2984-z. PMID:26898299.
   PubMed Web of Science ®Google Scholar
• Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al.. National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical Chem. 2008;54:e11–79. doi:10.1373/clinchem.2008.105601.
   PubMed Web of Science ®Google Scholar
• Kabawat SE, Bast Jr RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Path. 1983;2:275–85 doi:10.1097/00004347-198303000-00005.
   PubMed Web of Science ®Google Scholar
• Simsek H, Kadayifci A, Okan E. Importance of serum CA125 levels in malignant peritoneal mesothelioma. Tumour Biol. 1996;17:1–4. doi:10.1159/000217960. PMID:7501967.
   PubMed Web of Science ®Google Scholar
• Bateman AC1, al-Talib RK, Newman T, Williams JH, Herbert A. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression. Histopathology. 1997;30:49–56. doi:10.1046/j.1365-2559.1996.d01-562.x. PMID:9023557.
   PubMed Web of Science ®Google Scholar
• Zeimet AG, Marth C, Offner FA, Obrist P, Uhl-Steidl M, Feichtinger H, Stadlmann S, Daxenbichler G, Dapunt O. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol. 1996;62:384–9. doi:10.1006/gyno.1996.0253. PMID:8812537.
   PubMed Web of Science ®Google Scholar
• Oda M, Kozono H, Morii H, Azuma T. Evidence of allosteric conformational changes in the antibody constant region upon antigen binding. Int Immunol. 2003;15: 417–26. doi:10.1093/intimm/dxg036. PMID:12618486.
   PubMed Web of Science ®Google Scholar
• anda A, Bowen A, Greenspan NS, Casadevall A. Ig constant region effects on variable region structure and function. Front Microbiol. 2016;7:1–10. doi:10.3389/fmicb.2016.00022. PMID:26834723.
   PubMed Web of Science ®Google Scholar